Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor

Journal of Biological Chemistry

Volumn 289, Issue 48, 2014, Pages 33701-33711

  Abdul Ridha, Alaa ^a   Robert Lane, J ^a   Mistry, Shailesh N ^a   López, Laura ^a   Sexton, Patrick M ^a,b   Scammells, Peter J ^a   Christopoulos, Arthur ^a,b   Canals, Meritxell ^a  

^a MONASH UNIVERSITY   (Australia)

^b NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; ENZYME ACTIVITY; SCAFFOLDS;

EXTRACELLULAR LOOPS; MUSCARINIC ACETYLCHOLINE RECEPTORS; MUSCARINIC ACETYLCHOLINE RECEPTORS (MACHR); POSITIVE ALLOSTERIC MODULATOR; POSITIVE COOPERATIVITY; SITE DIRECTED MUTAGENESIS; STRUCTURE-FUNCTION RELATIONSHIP; TRANSMEMBRANE DOMAIN;

MODULATORS;

ACETYLCHOLINE; BENZOQUINAZOLINONE 12; BENZYLQUINOLONE CARBOXYLIC ACID; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; QUINOLINOL DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROPHOBICITY; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; AGONISTS; ALLOSTERISM; ANIMAL; BINDING SITE; CHEMISTRY; CHO CELL LINE; CRICETULUS; HAMSTER; HUMAN; METABOLISM; PHYSIOLOGY;

ACETYLCHOLINE; ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; HYDROXYQUINOLINES; RECEPTOR, MUSCARINIC M1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84912085331     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.604967     Document Type: Article

References (44)

1. Katritch, V., Cherezov, V., and Stevens, R. C. (2013) Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53, 531-556
2. Kruse, A. C., Hu, J., Kobilka, B. K., and Wess, J. (2014) Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development. Curr. Opin. Pharmacol. 16, 24-30
3. Conn, P. J., Christopoulos, A., and Lindsley, C. W. (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41-54
4. Jones, C. K., Byun, N., and Bubser, M. (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37, 16-42
5. Byun, N. E., Grannan, M., Bubser, M., Barry, R. L., Thompson, A., Rosanelli, J., Gowrishankar, R., Kelm, N. D., Damon, S., Bridges, T. M., Melancon, B. J., Tarr, J. C., Brogan, J. T., Avison, M. J., Deutch, A. Y., Wess, J., Wood, M. R., Lindsley, C. W., Gore, J. C., Conn, P. J., and Jones, C. K. (2014) Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology 39, 1578-1593
6. Shirey, J. K., Brady, A. E., Jones, P. J., Davis, A. A., Bridges, T. M., Kennedy, J. P., Jadhav, S. B., Menon, U. N., Xiang, Z., Watson, M. L., Christian, E. P., Doherty, J. J., Quirk, M. C., Snyder, D. H., Lah, J. J., Levey, A. I., Nicolle, M. M., Lindsley, C. W., and Conn, P. J. (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J. Neurosci. 29, 14271-14286
7. Stevens, R. C., Cherezov, V., Katritch, V., Abagyan, R., Kuhn, P., Rosen, H., and Wüthrich, K. (2013) The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat. Rev. Drug Discov. 12, 25-34
8. Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F., and Babu, M. M. (2013) Molecular signatures of G-protein-coupled receptors. Nature 494, 185-194
9. Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. M., Christopoulos, A., Felder, C. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. C., Wess, J., and Kobilka, B. K. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101-106
10. Abdul-Ridha, A., López, L., Keov, P., Thal, D. M., Mistry, S. N., Sexton, P. M., Lane, J. R., Canals, M., and Christopoulos, A. (2014) Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor. J. Biol. Chem. 289, 6067-6079
11. Canals, M., Lane, J. R., Wen, A., Scammells, P. J., Sexton, P. M., and Christopoulos, A. (2012) A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J. Biol. Chem. 287, 650-659
12. Ma, L., Seager, M. A., Wittmann, M., Jacobson, M., Bickel, D., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M., McCampbell, A., Gaspar, R., Shughrue, P., Danziger, A., Regan, C., Flick, R., Pascarella, D., Garson, S., Doran, S., Kreatsoulas, C., Veng, L., Lindsley, C. W., Shipe, W., Kuduk, S., Sur, C., Kinney, G., Seabrook, G. R., and Ray, W. J. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc. Natl. Acad. Sci. U.S.A. 106, 15950-15955
13. Dror, R.O., Green, H. F., Valant, C., Borhani, D. W., Valcourt, J. R., Pan, A. C., Arlow, D. H., Canals, M., Lane, J. R., Rahmani, R., Baell, J. B., Sexton, P. M., Christopoulos, A., and Shaw, D. E. (2013) Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 503, 295-299
14. Nawaratne, V., Leach, K., Felder, C. C., Sexton, P. M., and Christopoulos, A. (2010) Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J. Biol. Chem. 285, 19012-19021
15. May, L. T., Avlani, V. A., Langmead, C. J., Herdon, H. J., Wood, M. D., Sexton, P. M., and Christopoulos, A. (2007) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol. Pharmacol. 72, 463-476
16. Matsui, H., Lazareno, S., and Birdsall, N. J. (1995) Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol. Pharmacol. 47, 88-98
17. Lazareno, S., Dolezal, V., Popham, A., and Birdsall, N. J. (2004) Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65, 257-266
18. 1 receptor function in the central nervous system. ACS Chem. Neurosci. 1, 104-121
19. Melancon, B. J., Tarr, J. C., Panarese, J. D., Wood, M. R., and Lindsley, C. W. (2013) Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. Drug Discovery Today 18, 1185-1199
20. Tarr, J. C., Turlington, M. L., Reid, P. R., Utley, T. J., Sheffler, D. J., Cho, H. P., Klar, R., Pancani, T., Klein, M. T., Bridges, T. M., Morrison, R. D., Blobaum, A. L., Xiang, Z., Daniels, J. S., Niswender, C. M., Conn, P. J., Wood, M. R., and Lindsley, C. W. (2012) Targeting selective activation of M1 for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M1 positive allosteric modulator ML169. ACS Chem. Neurosci. 3, 884-895
21. Foster, D. J., Choi, D. L., Conn, P. J., and Rook, J. M. (2014) Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Neuropsychiatr. Dis. Treat. 10, 183-191
22. Nickols, H. H., and Conn, P. J. (2014) Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol. Dis. 61, 55-71
23. Nathan, P. J., Watson, J., Lund, J., Davies, C. H., Peters, G., Dodds, C. M., Swirski, B., Lawrence, P., Bentley, G. D., O'Neill, B. V., Robertson, J., Watson, S., Jones, G. A., Maruff, P., Croft, R. J., Laruelle, M., and Bullmore, E. T. (2013) The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int. J. Neuropsychopharmacol. 16, 721-731
24. Kuduk, S. D., and Beshore, D. C. (2012) Novel M1 allosteric ligands: a patent review. Expert. Opin. Ther. Pat. 22, 1385-1398
25. Kuduk, S. D., Beshore, D. C., DiMarco, C. N., and Greshock, T. J. (May 27, 2010) U. S. Patent WO 2010/059773
26. Kennedy, D. P., McRobb, F. M., Leonhardt, S. A., Purdy, M., Figler, H., Marshall, M. A., Chordia, M., Figler, R., Linden, J., Abagyan, R., and Yeager, M. (2014) The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers. Mol. Pharmacol. 85, 301-309
27. Ragnarsson, L., Wang, C. I., Andersson, A., Fajarningsih, D., Monks, T., Brust, A., Rosengren, K. J., and Lewis, R. J. (2013) Conopeptide rho-TIA defines a new allosteric site on the extracellular surface of the α1B-adrenoceptor. J. Biol. Chem. 288, 1814-1827
28. Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobilka, B. K., Haga, T., and Kobayashi, T. (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551
29. Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J., and Kobilka, B. K. (2012) Structure and dynamics of theM3 muscarinic acetylcholine receptor. Nature 482, 552-556
30. Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., and Schulten, K. (2005) Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781-1802
31. Shonberg, J., Herenbrink, C. K., López, L., Christopoulos, A., Scammells, P. J., Capuano, B., and Lane, J. R. (2013) A structure-activity analysis of biased agonism at the dopamine D2 receptor. J. Med. Chem. 56, 9199-9221
32. Motulsky H, C. A. (2004) Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting, Oxford University Press, New York
33. Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A., Shaw, D. B., Sexton, P. M., and Christopoulos, A. (2010) Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35, 855-869
34. Leach, K., Sexton, P. M., and Christopoulos, A. (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28, 382-389
35. Kenakin, T., and Christopoulos, A. (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216
36. Christopoulos, A. (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol. Sci. 19, 351-357
37. Kuduk, S. D., Chang, R. K., Di Marco, C. N., Ray, W. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., Hartman, G. D., and Bilodeau, M. T. (2011) Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series. Bioorg. Med. Chem. Lett. 21, 1710-1715
38. Hulme, E. C., Lu, Z. L., Saldanha, J. W., and Bee, M. S. (2003) Structure and activation of muscarinic acetylcholine receptors. Biochem. Soc. Trans. 31, 29-34
39. Lebon, G., Langmead, C. J., Tehan, B. G., and Hulme, E. C. (2009) Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. 75, 331-341
40. Keov, P., López, L., Devine, S. M., Valant, C., Lane, J. R., Scammells, P. J., Sexton, P. M., and Christopoulos, A. (2014) Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor. J. Biol. Chem. 289, 23817-23837
41. Mistry, S. N., Valant, C., Sexton, P. M., Capuano, B., Christopoulos, A., and Scammells, P. J. (2013) Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. J. Med. Chem. 56, 5151-5172
42. Conn, P. J., Jones, C. K., and Lindsley, C. W. (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30, 148-155
43. Valant, C., Felder, C. C., Sexton, P. M., and Christopoulos, A. (2012) Probe dependence in the allosteric modulation of a g protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Mol. Pharmacol. 81, 41-52
44. Kuduk, S. D., Di Marco, C. N., Saffold, J. R., Ray, W. J., Ma, L., Wittmann, M., Koeplinger, K. A., Thompson, C. D., Hartman, G. D., Bilodeau, M.T., and Beshore, D. C. (2014) Identification of a methoxynaphtalene scaffold as a core replacement in quinolizidinone amide M1 positive allosteric modulators. Bioorg. Med. Chem. Lett. 24, 1417-1420